태그 클라우드
- #$1.1 million contract
- #$25 million
- #$6.2M
- #'coronavirus'
- #'malaria']
- #'Radiology' journal
- #(Z)-endoxifen
- #000th patient milestone
- #179
- #2023 grants
- #2023-24 research fellowship awards
- #21-valent pneumococcal conjugate vaccine candidate
- #23andMe
- #2seventy bio
- #300 mg BID
- #340B Drug Pricing Program
- #4
- #505(b)(2) New Drug Application
- #505(b)(2) regulatory pathway.
- #853
- #A$80 million capital raise
- #A-T
- #A.G.P./Alliance Global Partners
- #aaa
- #AAV-based gene therapies
- #AB-101a
- #Abbreviated New Drug Application (ANDA)
- #Abbvie
- #AbbVie Biopharmaceutical
- #AbbVie's Humira
- #abdominal colorectal surgical site infections
- #ABEO
- #Abeona
- #Abeona Therapeutics
- #Abivertinib
- #ABMR
- #abnormalities
- #ABP 654
- #ABP-450
- #absorbed radiation dose
- #absorbed radiation dose correlation with improvement in overall survival
- #abstract
- #Abu Dhabi
- #Acasti
- #accelerated approval
- #access
- #access to drugs
- #acetazolamide
- #acneiform
- #Acquisition
- #ACROBioSystems
- #action dates
- #Actionable Clinical Intelligence (ACI) platform.
- #activist investor
- #ACU193
- #Acumen
- #acute and chronic kidney disease
- #acute lymphoblastic leukemia
- #Acute Myelogenous Leukemia (AML)
- #acute myeloid leukemia
- #acute myeloid leukemia (AML)
- #Acute Respiratory Distress Syndrome (ARDS)
- #Acute Suicidal Ideation and Behavior
- #ad
- #Adage Capital Partners LP
- #adalimumab-aacf
- #adc
- #Adcetris
- #Adcomm
- #ADCs (antibody drug conjugates)
- #add-on to standard of care
- #Adelaide South Australia location of the trial.
- #ADHD
- #ADME
- #ADMET
- #adrulipase
- #ADRX
- #ADSTILADRIN
- #adult stem cells
- #adults
- #ADVANCE study.
- #ADVANCE trial
- #Advanced Breast Cancer
- #advanced G/GEJ cancer
- #advanced melanoma
- #advanced solid tumors
- #advanced-stage disease
- #adverse event rates
- #adverse events
- #adverse events (AEs)
- #adverse food reactions
- #adverse reactions
- #advisory committee
- #advisory committee vote
- #ADX-2191
- #AECc analysis
- #Aedes mosquitoes
- #AEON Biopharma
- #AeriSeal® System followed by Zephyr® Valves
- #AF-PRS
- #AGAVE-201
- #AgeJET
- #ages 6-17 years-old.
- #aggressive breast cancers
- #Agile
- #agonistic anti-TNFR2 monoclonal antibody
- #agreement
- #agreement with NBP Pharma
- #AI
- #AI-driven molecular cardiovascular disease technologies
- #AI-powered drug R&D.
- #AI-Powered Lung Cancer Screening Solution
- #AI/cloud-based data analysis software
- #AI/computational methods for drug design
- #AIDD
- #AIM
- #AIM ImmunoTech
- #aiProtein® technology
- #Air Force
- #Aisa Pharma
- #Aitor González
- #Akari
- #Akili
- #AKS-452
- #Akston Biosciences
- #AL102
- #Alagille syndrome
- #Albiglutide
- #ALBRIOZA®
- #Alcoholic Liver Disease
- #Aldeyra
- #Aldeyra Therapeutics
- #Alexander Denner
- #Algorithms
- #Allergan
- #Allergan Aesthetics
- #allergic conjunctivitis
- #allergies
- #allergy
- #ALLOB
- #allogenic therapy
- #Allorion Therapeutics
- #allosteric inhibitor
- #Almeda Ventures
- #alpha cell subtypes
- #Alphyn
- #Alport syndrome
- #ALS
- #Altamira Therapeutics
- #Alter Pharma Group
- #alternative foods
- #alternatives
- #Alvotech
- #Alzheimer
- #alzheimer's disease
- #Alzheimer's disease diagnosis
- #Alzheimer's drug
- #Alzheimer’s disease
- #Amarin
- #AMD
- #American Academy of Sleep Medicine (AASM)
- #American Diabetes Association (ADA) Conference
- #American Diabetes Association's Annual Conference
- #American Society of Clinical Oncology (ASCO)
- #AmerisourceBergen Corporation
- #amgen
- #AML
- #Amneal Pharmaceuticals
- #Ampligen
- #AMX0035
- #amyloid-related imaging abnormalities (ARIA)
- #Amylyx Pharmaceuticals
- #amyotrophic lateral sclerosis
- #analytical development and GMP production
- #Anaphylm development program.
- #Andrei Floroiu (Vaxart's Chief Executive Officer)
- #androgenic alopecia
- #andros
- #anemia
- #Anesthesia
- #Aneuro
- #animal model
- #AnixaBiosciences
- #Ankylosing spondylitis
- #Annamycin
- #annual disease burden from norovirus in the U.S.
- #annual general and special meeting of shareholders
- #annual report
- #annual shareholder meeting
- #anterior cervical interbody fusion procedures
- #anterior cingulate cortex
- #anti-aging clinical trial
- #anti-alpha-synuclein antibodies
- #anti-anginal agent approved in the US in 2006
- #anti-Chitinase 1 small molecule candidate
- #anti-FcRn treatment
- #anti-HER2 monoclonal antibodies
- #anti-HER3 monoclonal antibodies
- #anti-PD1/PDL1 agents
- #anti-trust issues
- #Anti-tumor immune genes
- #anti-VEGF protein
- #Antibiotics
- #antibody
- #antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes
- #antibody drug conjugate (ADC)
- #antibody therapy
- #antibody-drug conjugate
- #antigen expressed by most prostate cancers
- #Antimicrobial Drugs Advisory Committee
- #antiviral library
- #antiviral research
- #APIs (active pharmaceutical ingredients)
- #Apnea Hypopnea Index
- #apolipoprotein E (ApoE) ε4 homozygotes
- #approval
- #approves
- #APX3330
- #Aquarius Population Health Limited
- #Aquestive Therapeutics
- #Arcatus
- #Arctic Vision
- #Ardelyx
- #ARDS drug
- #AREXVY
- #Argenx
- #Aria
- #Arkansas markets.
- #arthritis
- #articles of incorporation
- #Artificial Intelligence
- #artificial intelligence (AI)
- #artificial intelligence (AI) application.
- #aSAH patients
- #Ascelia Pharma
- #ascending doses
- #ASCO
- #ASCO 2024
- #ASCO Annual Meeting
- #ASH 2023
- #Asia Pacific.
- #ASIB
- #ASPIRE grants
- #Assets
- #Astellas Pharma
- #Astellas Pharma Inc.
- #asthma
- #astrazeneca
- #ASX: IMM
- #asymptomatic vaginal dysbiosis
- #at-home medical device
- #atezolizumab (Tecentriq®)
- #ATH-399A
- #atherosclerosis
- #atogepant
- #Atossa Therapeutics
- #atrasentan
- #audited financials
- #Auditor
- #Augmedics
- #augmented reality
- #AUROC (area under the receiver operating characteristic curve)
- #Aurora Spine
- #Australia
- #autoimmune conditions
- #autoimmune disease
- #autoimmune diseases
- #autoimmune diseases.
- #autoimmunity
- #autoinflammatory diseases
- #autologous therapy
- #AUX-001
- #Auxilius Pharma
- #Avanos Medical
- #AVROBIO
- #AVT04
- #AWARD
- #AWS Certified Solutions Architects.
- #AWS cloud-hosted environments
- #Axatilimab
- #Axsome
- #Ayala Pharmaceuticals
- #azacitidine and venetoclax.
- #B cell-mediated autoimmune diseases
- #BA/BE trial design
- #Baby
- #Balloon Catheter
- #Bangladesh
- #bankers
- #Barclays)
- #BARDA
- #barriers to access
- #barzolvolimab
- #Basal Cell Carcinoma (BCC)
- #Baseimmune
- #batoclimab
- #Bausch Health
- #Baylor College of Medicine
- #BBP-398
- #bcg
- #Befortus
- #behavior and mood between episodes
- #Belgium
- #Bellberry Human Research Ethics Committee (HREC)
- #BEN-8744
- #benchmark
- #benefit-risk profile
- #BENEV
- #Bespoke Gene Therapy Consortium
- #beta cells
- #beta-amyloid protein
- #Betacoronaviruses
- #bevacizumab (Avastin®)
- #BI-1206
- #Biden administration
- #bile acids
- #bile ducts
- #Bio
- #BIO International Convention
- #BioCardia
- #BioCity Biopharma
- #biocompatible gold nanorods
- #BioCryst
- #Biodexa Ltd- PNOC015 (MTD-201) Study- Patients with Diffuse Midline Glioma (DMG)- Manuscript publication- Pediatric patients- MTX110- Convection Enhanced Delivery (CED)- Dose-limiting toxicities- Overall survival (OS)- Historical data- Journa
- #bioequivalence/bioavailability clinical trial
- #Biogen
- #BioInvent
- #Biological Dynamics
- #biological insights
- #Biologics License Application
- #Biologics License Application (BLA)
- #biomarker
- #biomarker analyses.
- #biomarker data
- #biomarker study
- #biomarkers
- #biomarkers.
- #biomaterial
- #biomedical assets
- #Biomerica
- #Biomica
- #biopharma
- #biopharma buyout
- #biopharmaceutical company
- #biopharmas
- #Biophytis
- #BioRestorative
- #Biosciences
- #BioSenic
- #Biosimilar
- #biosimilars
- #biosimilars market entry.
- #biotech
- #biotech company
- #biotech research talent
- #Biotechnology
- #biotechs
- #BIOTRONIK
- #bipolar disorder
- #bispecific antibodies
- #bispecific antibody
- #bispecific autoimmune checkpoint inhibitor
- #Bitterroot Bio
- #Bitterroot Bio; Biotheus
- #bivalent norovirus vaccine candidate
- #BK virus
- #bla
- #BLA submission
- #bladder cancer risk
- #blas
- #blood brain barrier.
- #blood samples
- #blood samples analysis
- #blood volume measurement technology.
- #blood-based detection test
- #Blue Earth Diagnostics
- #bluebird bio
- #BMC426
- #BMC427
- #BMS
- #BMS checkpoint inhibitor
- #Board
- #board of directors
- #board representatives
- #board-certified radiologists
- #Body Mass Index labeling
- #body weight reduction.
- #BOND-003
- #bone density measurement
- #bone formation
- #bone mineral density
- #bookrunning managers
- #botulinum toxin complex
- #Brain activity
- #brain connectivity
- #brain metastasis in lung tumors.
- #brain scans
- #brain wave changes
- #brainstorm
- #brand identity.
- #Brand Institute
- #brand-name drugs
- #brand-name products
- #BRB-002
- #breakthrough in MDD research
- #breakthrough therapy certificate
- #Breakthrough Therapy designation
- #breast cancer
- #breast cancer patients
- #Breast Cancer Research and Treatment
- #breast density
- #Brent Dover
- #BRG1/BRM
- #briana banks
- #Briquilimab
- #Bristol Myers Squibb
- #Broncus
- #BRTX-100
- #Bruton’s Tyrosine Kinase
- #Bryan Schneider's study on toxic side effects from chemotherapy in Black breast cancer patients.
- #Bryostatin-1
- #BT50
- #BTK inhibitor
- #BTK inhibitor.
- #bundling
- #business combination
- #business update
- #Bylvay
- #bystander killing effect
- #c-Kit (CD117)
- #C9orf72
- #Caeregen
- #calcitonin gene-related peptide (CGRP) antagonists.
- #calcium-channel antagonist (CCB)
- #California Consumer Class.
- #CAMB
- #CAMP4
- #Camzyos
- #CAN008
- #canada
- #CANbridge Pharmaceuticals
- #cancer
- #cancer cells
- #cancer indications
- #cancer platform
- #Cancer Research UK
- #cancer stem cells
- #cancer therapeutics
- #cancer therapy
- #cancer treatment
- #cancer treatment.
- #cancer treatments
- #cancer-signaling pathways
- #CancerTherapy
- #candidate drugs
- #CannAmide™
- #Cantor Fitzgerald & Co.
- #capital
- #capital requirement
- #CAPOX
- #CAPS spectrum
- #CAR-NKs (chimeric antigen receptor natural killer cells)
- #CAR-T (chimeric antigen receptor T-cell therapy)
- #CAR-T trial
- #carbonic anhydrase (CAIX)
- #cardiac regeneration
- #CardiAMP
- #Cardio Diagnostics Holdings
- #cardio-immunology
- #cardiovascular complications
- #cardiovascular condition
- #cardiovascular diseases
- #cardiovascular risk
- #caregivers
- #Carl Icahn
- #Carl N. Kraus
- #Caroline Dorsa
- #Carrick Therapeutics- clinical trial collaboration- Arvinas- Pfizer- samuraciclib- vepdegestrant- Phase 1b/2 clinical trial- CDK7 inhibitor- estrogen receptor protein degrader- metastatic breast cancer
- #Cart
- #Cartesian Therapeutics
- #cash distribution
- #cash infusion
- #cash runway
- #cash runway extension
- #Castle Biosciences
- #Catalent
- #catheter lock solution
- #catheterizations
- #causes of breast cancer
- #CB307
- #CBRE
- #CCL24
- #CCR8 antibody
- #CD19 CAR T-cell therapies
- #CD19 CAR T-cell therapies.
- #CD20
- #CD3
- #CD30 surface protein
- #CD47
- #CD8 Treg Modulators
- #CDMO
- #CE marking
- #CEL-SCI
- #Celecoxib
- #cell and gene therapies
- #cell line development
- #Cell Publication
- #cell therapies
- #cell therapy
- #Cell Viability Assays
- #cell- and gene-therapy
- #Celldex Therapeutics
- #Celmatix
- #Centers for Medicare & Medicaid Services (CMS)
- #Centessa
- #Central Committee on Research Involving Human Subjects
- #central venous catheter
- #CEO
- #CEO transition
- #cerebral amyloid angiopathy (CAA)
- #cerebral hemorrhage
- #cerebral hemorrhage and infusion-related reactions and hypersensitivity Medicare coverage for new Alzheimer’s drugs CMS Administrator Chiquita Brooks-LaSure.
- #Cerebrospinal Fluid assays
- #cervical cancer screening
- #cervical interbody system
- #cervical intervertebral body space(s)
- #CF33
- #CFO
- #CG Oncology
- #CGCCs
- #ChAdOx
- #Chairman of Immutep
- #Chairwoman
- #CHALLENGE-MIG trial
- #Chamber of Commerce
- #Charcot-Marie-Tooth disease type 4J
- #Charles Dadswell
- #Check Valve Device.
- #checkpoint inhibitor
- #checkpoint inhibitors
- #checkpoint modifier
- #checkpoint therapy
- #chemistry manufacturing and controls (CMC)
- #chemo
- #Chemomab Therapeutics
- #chemosensitizer agent.
- #chemotherapy
- #chemotherapy agents
- #chemotherapy drug
- #chest X-ray analysis performance
- #Chief Medical Officer appointment
- #Chief Medical Officer Uwe Tigör
- #chikungunya vaccine
- #chimeric antigen receptor (rCAR-T)
- #China
- #China Health Authority
- #China Medical System
- #China National Intellectual Property Administration (CNIPA)
- #Chinese gMG population
- #Chinook Therapeutics
- #Chitotriosidase (CHIT1) inhibitor
- #CHMP
- #CHMP opinion
- #Chol
- #cholangiocytes
- #cholestatic pruritus
- #Christian Leduc
- #chronic autoimmune diseases
- #chronic graft versus host disease (cGVHD)
- #chronic HBV infection.
- #chronic hemodialysis
- #chronic inflammatory disease
- #Chronic kidney disease (CKD)
- #chronic myeloid leukemia
- #Chronic Obstructive Pulmonary Disease (COPD)/Emphysema
- #Chronic Pain
- #chronic pain conditions
- #chronic rhinosinusitis with nasal polyps
- #chronic spontaneous urticaria
- #chronic-stable angina pectoris
- #chymotrypsinogen
- #cilnidipine.
- #cincinnati
- #ciprofloxacin
- #circular economy
- #Circulating Tumor Cells (CTCs)
- #cirrhosis
- #City of Hope
- #class of 15 recipients
- #class-action lawsuit
- #classical Hodgkin lymphoma
- #Claudin 18.2
- #CLDN18.2 expression level
- #clear cell renal cell carcinoma (ccRCC)
- #cleared
- #Clearmind Medicine
- #Clearside
- #Clene
- #Cleveland Clinic
- #clinical
- #clinical activity
- #clinical applications
- #clinical benefit
- #clinical data
- #clinical data.
- #clinical development
- #clinical development.
- #clinical hold.
- #Clinical Immunology
- #clinical observations
- #clinical pharmacology plan
- #clinical program
- #clinical remission rate
- #clinical research
- #clinical responders.
- #clinical sites
- #clinical stage biopharmaceutical company.
- #clinical study
- #clinical supply agreement.
- #clinical symptoms improvement
- #Clinical Trial
- #clinical trial centers.
- #clinical trials
- #clinical updates
- #clinical-stage biopharmaceutical company
- #clinical-stage biotechnology company
- #clinical-stage pipeline
- #ClinicalTrial
- #clinician-collected sampling
- #Clinicians
- #clinicopathological indices
- #closing of the offering
- #cloud-based genomic and biomedical data access
- #CLS-AX
- #CLSD
- #CM-101
- #CMAX Clinical Research
- #CMS
- #CMS Administrator Chiquita Brooks-LaSure.
- #CMS grants Fresenius Kabi permanent product-specific Q-Code
- #CMS.
- #CMS2
- #CNM-Au8
- #CNS
- #CNS disorders
- #CNS-101
- #co-develop batoclimab in Greater China.
- #co-managers
- #CO2 balance
- #coefficient of fat absorption (CFA)
- #coefficient of nitrogen absorption (CNA)
- #cognition
- #cognition scores
- #Cognition Therapeutics
- #cognitive decline
- #cognitive decline reduction
- #cognitive dysfunction
- #Coherus Biosciences
- #cohort of 30 doctors
- #CoImmune- CMN-001- clinical development program- metastatic renal cell carcinoma (mRCC)- dendritic cell-based immunotherapy- autologous tumor RNA- phase 2b clinical trial- checkpoint inhibition therapy- lenvatinib/everolimus- Human Vaccines &
- #coinsurance
- #COL4A4 mutations
- #collaboration
- #collaboration agreement
- #collagen accumulation
- #collagen fiber alignment
- #Colli-Pee® device
- #colonoscopes
- #Columbus
- #Columvi
- #COM701
- #COM902
- #Combination
- #combination product.
- #combination treatment
- #Comirnaty vaccine
- #commercial launch
- #commercialization of product candidate EB-101
- #commercialization plans.
- #commercialization preparation
- #commercialize
- #common stock
- #companion analysis software
- #company
- #company culture
- #company culture.
- #complete hematologic response
- #complete remission
- #complete remission rate
- #complete responses (CR)
- #composition of matter
- #compound annual growth rate
- #compound candidates
- #Compugen
- #concomitant treatment with anticoagulant agents
- #conditional marketing authorisation application
- #confirmatory clinical study
- #confirmed objective response
- #congenital hereditary endothelial dystrophy
- #Connect
- #connective tissue growth factor
- #Constella Intelligence
- #Constitution
- #consultants
- #Continuance
- #contract
- #contract research organizations (CROs)
- #COOLIEF Cooled Radiofrequency product offering
- #copd
- #core symptoms
- #coREST inhibitor
- #CorMedix Inc.
- #coronary heart disease (CHD)
- #CoronaTcP
- #cortical folding
- #Corvus Pharmaceuticals- ciforadenant- preclinical data- mechanism of action- synergy- immune checkpoint inhibitors- Phase 1b/2 clinical trial- metastatic RCC- anti-CTLA-4 and anti-PD-1 therapies- JCA-AACR Precision Cancer Medicine Internationa
- #Cosmic study
- #cost-cutting
- #cost-effective
- #cough
- #COURAGE trial (2007)
- #coverage
- #coverage with evidence development (CED)
- #coverage.
- #covered entities
- #Coviccine Trivalent XBB.1.5-Recombinant COVID-19 Trivalent Protein Vaccine
- #covid vaccine
- #COVID-19
- #COVID-19 pandemic
- #Covid-19 patients
- #COX-2 gene expression.
- #CPMG
- #CPS≥1
- #CR
- #Crag Basson.
- #Crescendo
- #Cretostimogene
- #CRISPR Therapeutics
- #CRISPR therapy
- #crohn's disease
- #crohn’s disease
- #cryo-electron microscopy
- #Cryopyrin-associated periodic syndrome (CAPS)
- #Crystal Pharmatech
- #CSPC Group subsidiary
- #CT1812
- #CTR-107
- #Cumulus
- #cure rates
- #Curreio
- #Current Surgical
- #CurvaFix
- #CVS
- #cybersecurity
- #CYBRA
- #cyclobenzaprine HCl sublingual tablets)
- #cyclosporine ophthalmic solution
- #cystic fibrosis (CF)
- #cytokine reduction
- #cytokine reduction.
- #cytokine release syndrome (CRS)
- #cytopenia
- #cytotoxic payload release
- #D-PLEX100
- #Daiichi Sankyo
- #damage response signaling
- #Dana-Farber Cancer Institute
- #Daré Bioscience
- #DARE-HRT1
- #DARE-VVA1
- #DARIC technology
- #darmstadt
- #data
- #data acquisition systems
- #Data Analysis
- #data breaches
- #data collection
- #data processing
- #Datopotamab Deruxtecan
- #Daxor Corporation
- #Dayton Ohio
- #DBA
- #dd-cfDNA
- #DDI
- #DDR1 inhibition
- #DDR1 protein
- #DDW 2023
- #de novo generative design technology
- #Deadly
- #debt
- #debt payoff
- #debt repayment
- #debt servicing
- #DecisionDx-Melanoma
- #DefenCath
- #Defense Logistics Agency's Electronic Catalog (ECAT)
- #Defiance
- #definitive local therapy
- #Delta-Fly Pharma Inc.
- #dengue virus
- #Department of Defense's Distribution and Pricing Agreement (DAPA)
- #Department of Health – Abu Dhabi
- #depressive disorder
- #dermatological conditions.
- #dermatology/oncology application
- #Design
- #desmoid tumors
- #develop
- #develop proprietary multi-format biologics including bi-specific antibodies and ADCs with a high drug-to-antibody ratio for increased efficacy against drug-resistant cancers such as HER2-positive metastatic breast cancer
- #developer
- #developing
- #development milestone payments
- #device
- #device development activities.
- #DevOps
- #DEXA-C device
- #DEXA-CTM Multicenter Study
- #Dexmedetomidine Hydrochloride Injection
- #DFD-29
- #DFP-10917
- #DIA
- #diabetes
- #diabetes drug Actos (pioglitazone)
- #diabetes experts
- #Diabetic Foot Infections
- #diabetic foot ulcers
- #Diabetic kidney disease (DKD)
- #diabetic retinopathy
- #DiaCarta
- #diagnosis
- #diagnosis and treatment
- #diagnostic and therapeutic applications
- #Diagnostic Biochips
- #diagnostic test
- #diarrhea rate
- #Diazepam Nasal Spray
- #DIET
- #dietary interventions
- #difficult fractures
- #difficult to treat cancers.
- #Digestive enzymes
- #digital diagnostics
- #Digital Pathology
- #digital pathology software
- #Direct Biologics
- #directed protein evolution
- #Directors
- #Diros Technology
- #dirsorder
- #DIS platform
- #Discount Hub solution.
- #disease control rate (DCR)
- #disease history
- #disease progression
- #disease progression model (DPM)
- #diseases
- #disinhibited behavior
- #disparities
- #DISTRESS
- #Distribution
- #Distribution Agreement
- #diverse researchers
- #DKN-01
- #DMB-3115
- #DMGs
- #DNA hypomethylation
- #DNAnexus
- #Dose
- #dose limiting toxicities (DLTs)
- #dose optimization study
- #dose titration strategy.
- #dose-ranging Phase 2 study
- #dosing
- #dosing protocol
- #dosing regimen
- #dosing schedule
- #double extortion
- #double-blind
- #Down Syndrome
- #doxorubicin
- #Dr Julian Kenyon
- #Dr. Alessandro Marcello
- #Dr. Chirinjeev Kathuria.
- #Dr. Jack A. Elias
- #Dr. James F. Cummings (Vaxart's Chief Medical Officer)
- #Dr. Reddy's
- #Dr. Russell Howard
- #dronabinol (THC)
- #Drug
- #drug availability
- #Drug Delivery
- #drug development
- #drug development and manufacturing company
- #Drug Discount Management
- #drug discovery
- #drug discovery project
- #drug manufacturer overpayment
- #drug manufacturing standards
- #drug price negotiation program
- #drug prices
- #drug pricing reform.
- #drug research and development
- #drug resistance
- #Drug Shortages list
- #drug substance manufacturing scale-up process
- #drug-free PTSD treatment
- #drug-free treatment
- #drug-resistant breast cancer
- #Drugs
- #dry eye disease.
- #dry-eye disease
- #DSMB
- #DTI imaging
- #Dubai
- #Duchenne muscular dystrophy
- #Dulaglutide
- #dupixent
- #duplicate discounts
- #duration of response (DOR)
- #durvalumab.
- #dysbiosis resolution
- #early breast cancer
- #Early-Stage Breast Cancer
- #early-stage lymphoma
- #EASL 2023
- #East
- #easy-to-use workflow- droplet digital PCR- researchers - percentage and precise quantification of dd-cfDNA.
- #EB-101
- #EB-101 Biologics License Application (BLA) submission
- #EB-373
- #Ebola virus
- #ECC4703
- #ECC5004
- #Eccogene
- #Economy
- #Edesa Biotech
- #EDIT-301
- #Editas Medicine
- #EdiTHAL trial
- #EdiTHAL trial.
- #Edwin J. Tucker
- #EEG
- #efficacy
- #efficacy data
- #efficacy signals
- #Efficacy Threshold
- #efficiency
- #Effl
- #efinopegdutide
- #eftilagimod alpha
- #Eganelisib
- #eGfR
- #EGFR-mutated non-small cell lung cancer
- #egg freezing
- #egg freezing protocols
- #Eisai
- #Eitan
- #Elacestrant drug
- #elderly
- #Election
- #electricity consumption
- #electroCore
- #electronic medical record (EMR) integration
- #electronic prescription (eRx)
- #Elevation Oncology
- #eligibility
- #Eliquis
- #Elizabeth Ng
- #Eloxx
- #Eloxx Pharmaceuticals
- #ELX-02
- #EMA
- #emavusertib
- #Embr Labs
- #emerging markets
- #Emgality
- #Emirate of Abu Dhabi
- #employee engagement
- #employee retention
- #employee retention strategy
- #end users
- #End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)
- #ENDO 2023 Annual Conference
- #Endo International
- #Endocrine Therapies.
- #Energizing Effects
- #ENERGY-1 trial
- #engraftment analysis
- #enhanced adrulipase formulation
- #Enochian BioSciences
- #eNOfit™ (Inhaled Nitric Oxide Delivery System)
- #ENPP1 Deficiency
- #Enrol
- #Enroll
- #enrollment
- #enrollment update
- #Ensitrelvir
- #enteric microgranule delivery formulation
- #ENVB
- #EO-3021
- #eosinophilic esophagitis (EoE)
- #epcoritamab
- #Epidermal Growth Factor Receptor Inhibitors (EGFRi)
- #epigenetic and genetic biomarkers
- #Epigenetic Changes
- #epigenetic control
- #epilepsy patients
- #episodic migraine
- #episodic or chronic migraine
- #epithelial tumors
- #Epkinly
- #equipment
- #equity
- #Equity Incentive Plan
- #Er-Kim
- #Erasmus Medical Center
- #EryDel
- #ESGAR Annual Meeting
- #ESH
- #ESMO GI Annual Congress 2023
- #esophagus cancer
- #essential thrombocythemia (ET)
- #estrogen
- #estrogen receptor-positive (ER+)
- #estrogen-based therapies.
- #ethics approval
- #EUA
- #Europe
- #European Association for the Study of the Liver annual congress
- #European Hematology Association (EHA)
- #European Hematology Association 2023 Hybrid Congress.
- #European Medicines Agency.
- #European Patent Office
- #European Union (EU)
- #European Union.
- #EU’s European Commission investigation and vetoing of buyout and divestment order for GRAIL acquisition by Illumina due to anti-trust violation finding by FTC.
- #Evergreen Theragnostics
- #Evidity Health Capital
- #exagamglogene autotemcel
- #exagamglogene autotemcel (exa-cel)
- #excise tax penalty
- #exclusive agreement with Applied Biomedical Science Institute (ABSI)
- #exclusive licensing deal
- #exclusive rights
- #exercise price
- #ExoCoBio
- #exocrine pancreatic insufficiency (EPI)
- #ExoFlo
- #ExoPTEN
- #Expansion
- #experimental treatments
- #EXPERT
- #Expert Market
- #explore
- #extension
- #eye itchiness
- #eye redness
- #F-star
- #facility
- #fair market competition
- #fallopian tube
- #false positive detections
- #familial cold autoinflammatory syndrome (FCAS)
- #farnesyl transferase inhibitor.
- #fast progressors
- #FB101
- #Fcab™ and tetravalent mAb² ™ platforms
- #fda
- #FDA acceptance
- #FDA approval
- #FDA approval determination.
- #FDA approval.
- #FDA approved treatment.
- #FDA Breakthrough Device Designation
- #FDA clearance
- #FDA cleared
- #FDA Emergency Use Authorization
- #FDA Fast Track
- #FDA feedback
- #FDA meeting
- #FDA panel
- #FDA recommendations
- #FDA reference listed drugs
- #FDA regulatory clearance
- #FDA review
- #FDA-approved
- #FDA-approved drugs
- #FDA-approved prescription pharmaceutical products
- #FDA-approved treatment
- #FDA-approved treatments
- #FDA-cleared
- #FDA.
- #Federal health plans
- #federal healthcare providers
- #Federal Supply Schedule (FSS)
- #Federal Trade Commission (FTC)
- #Federation of Clinical Immunology Societies (FOCIS 2023)
- #FemAid
- #Female Incontinence
- #FemaSeed®
- #Femasys
- #FemCath
- #Ferring Pharmaceuticals
- #fertility treatments
- #FHD-286
- #FHD-286 combination study
- #fibro-inflammatory diseases
- #fibroblasts
- #FibroGen
- #Fibromyalgia
- #fibrosis and cholestasis.
- #fibrosis and inflammation markers.
- #fibrosis-driven indications.
- #fibrotic and inflammatory disease processes
- #fibrotic diseases
- #Fierce Biotech
- #Fifth Amendment
- #final data and Phase II read-outs respectively
- #finances
- #financial advisors (Goldman Sachs & Co. LLC
- #Financial Report
- #financial results
- #financing
- #financing.
- #Finland
- #FinVector Oy
- #First Amendment
- #first session
- #First Wave BioPharma
- #First-in-Human clinical trial
- #first-line treatment
- #first-time awards and renewals
- #first-void urine collection device
- #FISHER
- #Flotufolastat F 18
- #Flow Electroporation
- #FLT3 mutation
- #FLT3 mutations
- #fm
- #FOCIS 2023
- #focus
- #Foghorn Therapeutics
- #follicle stimulating hormone (FSH) injections
- #follow-on study
- #food delivery
- #food effect on pharmacokinetics
- #food intolerances
- #Fortrea
- #forward purchase agreements.
- #Fosun Pharma
- #fracture rate
- #Fragility Fractures
- #france
- #Francis deSouza
- #Freespira
- #Fresenius Kabi
- #Freya Biosciences
- #front-line combination study
- #FSD Pharma Inc.
- #FSH receptor (FSHR) agonist drug
- #Fulcrum
- #full approval
- #Full Study Protocol.
- #fully-human multi-target immune modulating therapeutic
- #function
- #functional constipation
- #functional cure
- #Funding
- #future clinical development
- #FutureSearch Trials of Neurology
- #G protein-coupled receptor (GPCR) family of proteins
- #Ga 68 DOTATOC Injection
- #galcanezumab-gnlm
- #Gallup study
- #gamma secretase inhibitor
- #gastric cancer
- #Gastrin-17 drug
- #gastro-intestinal autoimmune disorders.
- #gastroesophageal cancers
- #gastrointestinal and infectious diseases management
- #gastrointestinal diseases
- #GBM
- #GBP410
- #gemcitabine
- #Gene editing
- #gene editor EDIT-301
- #gene therapies
- #Gene therapy
- #gene-edited cell therapeutics
- #GeneCentric
- #GeneDx
- #Genentech
- #generalized myasthenia gravis
- #Generalized Myasthenia Gravis (gMG)
- #generic products
- #generic version
- #genetic
- #genetic disease
- #genetic factors
- #genogroups GI and GII
- #genomics
- #GentiBio
- #George
- #George Washington UNIVERSITY
- #Germany
- #GI.1 strain
- #Giant Axonal Neuropathy (GAN)
- #GigaAssay technology
- #GII.4 strain
- #Glau
- #glioblastoma (GBM)
- #glioblastoma multiforme (GBM)
- #Global clinical program.
- #global cohort
- #global leader in laboratory services.
- #glofitamab
- #GLP toxicology study
- #GLP-1
- #GLP-1 RA
- #GLP-1 receptor agonist
- #GLP-1/glucagon receptor co-agonist
- #GLP-2
- #GLP-2 유사체
- #glucocorticoid hormone
- #glycopyrrolate injection
- #GMP-grade material
- #GMRx2
- #gold nanocrystals
- #government contract organizations
- #grading
- #GRAIL acquisition
- #grant
- #grants
- #greenhouse gas protocol
- #Grifols
- #gross proceeds
- #growth
- #gsk
- #GSK.
- #GTX-104
- #Guggenheim Securities.
- #gyrification index
- #H.C. Wainwright & Co.
- #H.I.G. Capital
- #H1 2024
- #Hae
- #HALO software
- #halt
- #Hanmi Pharmaceutical
- #Harbour BioMed
- #harmony
- #HDAC6 inhibitor
- #head and neck cancer
- #HEALEY ALS Platform Trial
- #health
- #Health Canada approval.
- #health equity
- #health management
- #health plans
- #healthcare
- #healthcare access
- #healthcare advancements
- #healthcare investors
- #healthcare sector
- #healthcare technology.
- #Hebrew University of Jerusalem.
- #Helicobacter pylori infection
- #Heligenics
- #hematocrit control
- #hematologic malignancies
- #hematological malignancies
- #hematological tumors
- #hemoglobin levels
- #Hepatic Impairment Study
- #Hepatitis B
- #hepatitis B virus (HBV)
- #hepatocellular carcinoma (HCC)
- #Heqet Therapeutics
- #Herceptin.
- #Hermansky-Pudlak syndrome (HPS)
- #HFB200301
- #HHS
- #Hidradenitis suppurativa
- #HiFiBiO Therapeutics
- #high drug-to-antibody ratio
- #high-accuracy AI model
- #high-accuracy AI model (Lunit INSIGHT CXR)
- #high-risk children
- #high-risk infection
- #Hillstream
- #Hillstream BioPharma
- #Himed
- #hiring
- #histological clearance of cancer cells
- #HMC
- #HML
- #HMPL-415
- #Horizon Therapeutics
- #hormone injections for treating infertility
- #hormone therapy
- #hormone-free treatment
- #Hospital
- #hospitals.
- #Host-Directed Therapeutics (HDTs)
- #Hoth
- #Hoth Therapeutics
- #HPV screening
- #HPV16-positive cancers
- #HREC
- #HSC gene therapy portfolio
- #HSCT-TMA
- #HT-001
- #HT-KIT
- #hTERT
- #HTN
- #human embryonic stem cells
- #Human Virology
- #humanized mice
- #humanized mouse models
- #Humira
- #HUTCHMED
- #Hypertension
- #hypogyrification
- #hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC)
- #I&I
- #I-SPY 2 Clinical Trial
- #Ibrutinib
- #IBS
- #IceCure Medical Ltd.
- #ICGEB
- #ICP-488
- #IDACIO
- #IDH co-mutations
- #Idiopathic pulmonary fibrosis
- #IgA
- #IgA nephropathy (IgAN)
- #IgAN
- #IHL-42X
- #IHL-675A
- #Iktos
- #IL-12
- #IL-18 agent
- #IL-1β expression
- #IL-23
- #IL-23 cytokines
- #IL-27 antibody
- #illnesses
- #illumina
- #Imfinzi
- #Immatics
- #immune cells
- #immune checkpoint inhibitor
- #immune checkpoint inhibitors.
- #immune escape capability
- #immune excluded tumors
- #immune exclusion
- #immune exclusion tumors
- #Immune Response
- #Immune Surveillance Genes
- #immune system
- #immune system.
- #immune-checkpoint inhibition
- #immune-mediated diseases
- #immunization
- #immuno-oncology targets
- #immuno-oncology therapies
- #immunocompromised people
- #immunocompromised.
- #immunogenicity
- #immunogenicity data
- #immunogenicity.
- #immunoglobulin A nephropathy (IgAN)
- #Immunology
- #immunology space
- #immunotherapeutic
- #immunotherapeutic candidate
- #immunotherapies
- #immunotherapy
- #Immutep
- #IMP761
- #implantable cardiac monitor
- #Imugene
- #in vitro fertilization (IVF)
- #in vivo electrophysiology
- #in vivo electrophysiology solutions
- #inaccurate drug discount claims
- #Inari Medical
- #Inc.
- #Incannex
- #Incannex Healthcare Limited
- #inclusion criteria
- #incurable
- #incyte
- #IND
- #IND opening
- #independent Contract Research Organization
- #independent data monitoring committee
- #India
- #Indian Health Services (IHS)
- #Indianapolis
- #Indica Labs
- #indication expansion
- #Industry
- #industry participants
- #infants
- #infants aged 42 to 89 days
- #Infectimune T cell-activating platform.
- #Infection
- #infertility evaluation
- #infertility rates
- #infertility treatment
- #Infinity
- #Inflammasome ASC Inhibitor IC 100.
- #inflammasome pathway
- #Inflammation
- #inflammatory bowel disease
- #Inflammatory Bowel Diseases
- #inflammatory bowel disorder
- #inflammatory cytokine.
- #inflammatory cytokines
- #inflammatory disease
- #inflammatory diseases
- #inflammatory diseases.
- #inflammatory markers change.
- #inflammatory signaling
- #inflation rate
- #inflation reduction act
- #Influenza
- #influenza A
- #inFoods IBS test.
- #information technology (IT) system
- #infrared light device
- #infusion-related reactions and hypersensitivity
- #infusion-related reactions and hypersensitivity.
- #inhibition effect on intraocular neovascularization
- #initiate
- #injectable fertility drugs
- #InnoCare
- #innovation
- #innovative therapeutics
- #Inogen
- #Inozyme Pharma
- #insemination product.
- #Insights
- #Inspira
- #Inspire Medical Systems
- #institutional investors
- #Insula
- #insulin secretion
- #insurance coverage process
- #IntelGenx
- #intellectual property estate
- #Intellia Therapeutics
- #intensive care setting
- #interbody spacer(s)
- #Intercept Pharmaceuticals
- #INTERCEPT-AD
- #interim analysis
- #interim head
- #Intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC)
- #International Centre for Genetic Engineering and Biotechnology
- #International Classification of Sleep Disorders Third Edition (ICSD-3)
- #International Conference on Malignant Lymphoma (ICML)
- #interstitial lung diseases
- #interventional radiologists
- #intestinal barrier
- #intestinal damage
- #intra-abdominal adhesions
- #intracystic LSAM-PTX
- #intrahepatic CD8+ T cells
- #intranasal administration
- #intranasal racemic ketamine
- #intranasal therapy
- #intrauterine catheter
- #intravaginal ring
- #Intravail absorption enhancer.
- #intravenous infusion
- #intravitreally delivered AAV gene therapy
- #Intrommune
- #invasive breast cancer
- #investigational agent
- #investigational anti-PD-1 immune checkpoint inhibitor
- #investigational antibody
- #investigational drugs
- #investigational long-acting antibody.
- #investigational neuroactive pherine therapeutics.
- #Investigational New Drug (IND)
- #Investigational New Drug (IND) application
- #Investigational New Drug Application (IND)
- #investigational programs
- #Investigational SKG0106
- #investigational treatments.
- #investigators and patients
- #Investment
- #Investors
- #Invivyd
- #invoX Company
- #INZ-701
- #IO Biotech
- #IO102-IO103
- #Iot
- #IPO
- #ipos
- #Ipsen/Albireo
- #IPSOS
- #IPSOS trial
- #IRAKIMiD Degrader KT-413
- #IRB approval
- #Ironwood Pharmaceuticals
- #ISCHEMIA trial (2020)
- #ISET
- #islet transplantation
- #Italy Mexico South Korea U.S.
- #itruvone
- #IVF procedures
- #J&J
- #JAK2V617F allele burden
- #Januvia.
- #Jasper Therapeutics
- #JBI-2174
- #JBI-2174 PD-L1 inhibitor for brain tumors.
- #JBI-778
- #JBI-802
- #JCO Precision Oncology
- #Jeff Fritz
- #Jeffery Lancet
- #job postings
- #job search
- #Johns Hopkins School of Medicine
- #joint bookrunning managers
- #joint efforts
- #joint research program
- #Journal for ImmunoTherapy of Cancer
- #Journal for ImmunoTherapy of Cancer (JITC)
- #Journey Medical Corporation
- #Jubilant Radiopharma
- #Jubilant Therapeutics
- #July 2023
- #justifications
- #juvenile idiopathic arthritis
- #K2 HealthVentures
- #Kalderos
- #Kamada
- #Kate Therapeutics
- #Kathy Seidl Ph.D.
- #KEDRAB
- #Kedrion
- #key opinion leader event
- #key opinion leaders
- #Keytruda
- #KEYTRUDA (Pembrolizumab)
- #KEYTRUDA®
- #kidney damage
- #kidney failure
- #KIR x CD8 targeting bispecific CD8 Treg modulator
- #Kisqali
- #KKR
- #Kleine-Levin Syndrome Foundation
- #KLS
- #Kojin Therapeutics
- #Korea University Medicine
- #Krystexxa
- #KSA
- #KTRA
- #Kuopio
- #Kura Oncology
- #Kymera Therapeutics
- #Kyverna
- #LAB
- #LABCORP
- #Labour and Welfare (MHLW)
- #Lactobacillus-dominated microbiome
- #LAG-3 agonist
- #large surface area microparticle (LSAM)
- #large-scale dataset
- #late-line metastatic uveal melanoma
- #late-stage and expanding clinical development pipeline
- #late-stage clinical development
- #late-stage trials in head and neck cancer and metastatic and triple negative breast cancer
- #Launch
- #launch preparations
- #lawsuit
- #lawsuits
- #LB-100
- #LB1148
- #LDT
- #lead candidates
- #lead managers
- #lead optimization studies by 2025.
- #lead product
- #lead product candidate
- #leader
- #leading institutions
- #leap
- #Lecanemab
- #legacy software systems
- #legal counsel
- #legal counsel (Jones Day and Hogan Lovells)
- #LELANTOS-1 trial
- #leptomeningeal metastases (LM)
- #Leqembi
- #leukemia treatment
- #LGI values
- #LianBio
- #Liberate Medical
- #LIBERTY Robotic Surgical System
- #Libervant (diazepam) Buccal Film
- #library of antiviral drug candidates
- #licence agreement
- #license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes
- #licenses technology
- #licensing agreement
- #life sciences industry
- #life sciences organizations
- #lifestyle factors
- #lifestyles
- #LiLii
- #Lilly
- #limited government
- #linaclotide
- #LINEAGE
- #Linux
- #Linzess
- #lipid disorders.
- #Liraglutide
- #live-attenuated vaccine candidate.
- #liver damage
- #Liver disease
- #liver fibrosis
- #liver histological improvement endpoints
- #liver imaging
- #liver inflammation
- #LiVeritas
- #Lixisenatide
- #LIXTE Biotechnology Holdings
- #LLC
- #LNAplus ASO
- #locally advanced or metastatic disease
- #long-term effects
- #loud quitting
- #Lovell Government Services
- #Lovell streamlines acquisition process
- #lovotibeglogene autotemcel (lovo-cel)
- #low-accuracy AI model trained with limited data from Lunit INSIGHT CXR
- #lower respiratory tract disease
- #lower respiratory tract disease (LRTD)
- #Lower-Risk Myelodysplastic Syndrome (LR-MDS)
- #LSD
- #LSD1 and HDAC6 inhibition
- #LSD1 and HDAC6 inhibitors
- #LSD1 inhibitor
- #Lung
- #lung cancer
- #lung cancer and ovarian cancer.
- #lung cancer patients
- #lung function
- #Lunit
- #lupus nephritis disease activity
- #Lymphoma
- #Lynparza
- #M&A
- #M.D.
- #M42
- #maa
- #Madrigal Pharmaceuticals
- #MAESTRO-NASH biopsy trial
- #major causes of death in Mexican adults.
- #major depressive disorder
- #majority interest
- #Makya™ generative AI technology
- #male infertility
- #male sperm count and viability
- #male-pattern baldness
- #malignant pleural mesothelioma.
- #Malware
- #mammary gland ducts development and breast cancer risk
- #manage
- #managerial influence.
- #manufacturing activities
- #manufacturing facilities investment
- #manufacturing sites
- #Manuscripts
- #MARIO-8
- #Mark Rothera
- #market potential.
- #market share increase
- #market size
- #marketing exclusivity.
- #marketing expertise
- #marketing submissions
- #Markets
- #Mast Cell-Derived Cancers
- #mast cells
- #Matthew Brady
- #MaxCyte
- #maximum tolerated dose (MTD)
- #Mayo Clinic
- #Mazindol ER
- #mCRPC
- #MD
- #MDD
- #MDR-001
- #MDRP Discount Monitoring solution
- #mds
- #MEAI
- #mechanical ventilation
- #MED
- #median overall survival (OS)
- #Medicaid Drug Rebate Program (MDRP)
- #medical
- #medical conditions
- #medical data
- #Medical Device
- #medical device design and development
- #Medical Devices
- #Medical Ethics Review Committee Erasmus MC
- #medical gas services
- #medical industry
- #medical research
- #Medical Technology Associates
- #Medicare coverage
- #Medicare drug negotiation program
- #Medicare Part B
- #Medicare program
- #medication
- #medication development
- #medicinal cannabinoid pharmaceutical products
- #medtech
- #melanoma-specific mortality
- #Melinta
- #Memorandum of Understanding (MoU)
- #menin inhibitor
- #menopause
- #merck
- #Merck's anti-PD-1 therapy
- #Mercury
- #mesenchymal stem cells
- #mesothelioma
- #metabolic diseases
- #metabolic disorders
- #metabolic factors
- #metabolic syndrome
- #metanalysis
- #metastatic breast cancer
- #metastatic cancer
- #metastatic cancer market
- #metastatic diseases
- #metastatic pancreatic ductal adenocarcinoma (PDAC)
- #metastatic uveal melanoma
- #methods of use claims
- #methotrexate injection
- #Mexico City Prospective Study
- #Micro-RayStation
- #microbe
- #Microbot Medical
- #microRNA-10b
- #mid-stage studies
- #migraine
- #migraine drug
- #migraine treatment
- #Mike Simmons
- #mild-to-moderate
- #Mild-to-Moderate Alzheimer's Disease
- #MILESTONE
- #milestone achievement.
- #Military Health System (MHS)
- #military personnel
- #Milla Pharmaceuticals
- #Milla Pharmaceuticals Inc.
- #MindBio
- #MindRank
- #minimally invasive treatments.
- #minimum safety guidelines.
- #Ministry of Health
- #Minnetronix
- #Minocycline Hydrochloride Modified Release Capsules
- #minority interest
- #Misconduct
- #MIT
- #mitochondria function
- #mixed-lineage leukemias
- #MK-7240
- #MLD
- #Moderna
- #Moderna.
- #modernize regulatory paradigm
- #molecular response
- #Molecular Templates
- #Moleculin
- #Molecure
- #momelotinib
- #monitoring systems.
- #monoclonal antibodies
- #monoclonal antibody
- #monoclonal antibody candidate
- #monopolistic positions
- #monovalent shot
- #Montelukast
- #MoonLake Immunotherapeutics
- #Morquio A syndrome
- #motor function
- #motor skills impairment
- #mouse model
- #Mozart Therapeutics
- #Mpe
- #MPN and AML treatment
- #MRI contrast agent
- #MRI scan
- #MRNA
- #mRNA technology
- #MTA
- #MTAP
- #MTM1 gene
- #MTX-101
- #MTX110
- #mucinous pancreatic neoplasms.
- #Muckle Wells syndrome (MWS)
- #mucosal and cell-based assay data
- #multi-antigen immunotherapeutic candidate containing four prostate-associated antigens: PSA
- #multi-centre
- #multi-modular Treg cell therapies
- #multi-site model
- #Multikine
- #multiple formats including bi-specific antibodies
- #multiple medications
- #Multiple Myeloma
- #multiple sulfatase deficiency (MSD)
- #muscle disorder
- #mutant EGFR and BTK dual inhibitor
- #mutations
- #MVA
- #MVM Partners
- #MVOR-1
- #MVOR-2
- #myasthenia gravis
- #MYC
- #Myc protein
- #MYD88-mutant B-cell malignancies.
- #myelin disruption
- #Myelodysplastic Syndromes (MDS)
- #myelofibrosis
- #myelofibrosis.
- #MyoAAV capsid
- #Myriad
- #MyRisk
- #N.C.
- #N/A
- #nab-paclitaxel
- #NAFLD
- #name change.
- #naNO-COVID
- #NanOlogy
- #nanoparticles
- #nanotherapeutic platform
- #Nantahala Capital Management LLC
- #Nasdaq
- #Nasdaq Rules
- #NASDAQ Stock Market
- #NASDAQ: IMMP
- #Nash
- #NASH patients
- #Nathan Merrill
- #National Cancer Center
- #National Cancer Institute's SEER Program Registries
- #National Cancer Institute.
- #National Institutes of Health.
- #National Medical Products Administration (NMPA)
- #National Medical Products Administration of China
- #National Organization for Rare Disorders.
- #National Third-Party Payer Class
- #natural history data
- #Natural Natural THCV
- #natural saline and air contrast
- #NAVAL-1 Trial
- #NCC Group
- #NCI
- #NCT05322473
- #NCT06001788
- #NCT06035120
- #NCT06111235
- #NDA
- #NDA approval
- #NDA submission.
- #Nectero
- #Nectin-4
- #negative opinion
- #NEI
- #Neil Brewis Ph.D.
- #neoadjuvant treatment
- #neonatal onset multisystem inflammatory disease (NOMID)
- #neostigmine methylsulfate
- #neovascular age-related macular degeneration (nAMD)
- #Nerlynx™
- #nerve cells
- #nerve regeneration
- #net income forecast.
- #net loss
- #net proceeds
- #Netherlands
- #Neural
- #neural circuits involved in emotional regulation
- #neural network
- #neurodegenerative disorders
- #neuroendocrine small cell lung cancer (SCLC)
- #Neuroendocrine Tumor Diagnostic OCTEVY™
- #neuroendocrine tumors
- #neurofilament light chain
- #neurological disease pathology
- #neurological diseases.
- #neuroprotective processes.
- #neuropsychiatric disorder.
- #neuroscience drug discovery
- #neurosciences
- #NeuroSense Therapeutics
- #neurostimulation technology.
- #Neurotrials Research Inc.
- #neutralization activity
- #neutralizing antibody titers
- #neutropenia.
- #New Drug Application
- #New Drug Application (NDA)
- #New Drug Application filing
- #new drug approvals- therapeutic value- patients- study- FDA- European Medicines Agency (EMA)- cancer disorders- supplemental indications- first indication approvals- second line approvals- third line approvals- drug pricing- University of Z
- #new drug discovery
- #New Jersey campus.
- #New Mexico
- #New Scientific Research Funding
- #New York University Medical School
- #NewBiologix SA
- #newly diagnosed primary central nervous system lymphoma (PCNSL)
- #next generation of researchers
- #next-generation multi-specific antibodies
- #NFL
- #NfL levels
- #NIH
- #NIH funding
- #nimodipine
- #nirsevimab
- #NLR family pyrin domain containing 3 (NLRP3)
- #NLRP3
- #NLRP3-mediated diseases.
- #NLS Pharmaceutics
- #NMIBC
- #nomacopan
- #Non-Alcoholic Steatohepatitis
- #non-coding RNAs
- #Non-Drug
- #non-GCB DLBCL
- #non-Hodgkin lymphoma
- #non-invasive neurostimulation devices
- #non-muscle invasive bladder cancer (NMIBC)
- #non-opioid-based treatments
- #non-small cell lung cancer (NSCLC)
- #non-small cell lung cancer.
- #non-squamous non-small cell lung cancer
- #Non-Surgical
- #Nonalcoholic Steatohepatitis (NASH)
- #nonsense mutations
- #nonsense mutations.
- #Noregen
- #norovirus program next steps
- #North America
- #North American Menopause Society (NAMS)
- #Novaliq
- #Novartis
- #Novartis and Genentech CEOs
- #Novavax
- #novel LAG-3 immunotherapies
- #novel treatment combination for tumor cells repair and growth prevention in TNBC patients
- #Novo Nordisk's semaglutide
- #Novosanis
- #Novotech
- #NPHP5 retinal degeneration
- #NRx Pharmaceuticals
- #NRX-101
- #NSCLC
- #NSCLC setting perioperative treatment with Keytruda plus chemotherapy in the KEYNOTE-671 study reduced the risk of disease recurrence. Moderna and Merck's personalized cancer vaccine mRNA-4157 in combination with Keytruda reduced the risk of spread to ot
- #NurExone Biologic Inc.
- #NurOwn
- #Nurtec
- #Nuvaxovid
- #Nymox
- #OAR 플랫폼
- #OATD-01
- #obesity
- #obeticholic acid (OCA)
- #Objective responses
- #obstructive sleep apnea
- #obstructive sleep apnoea
- #obstructive sleep apnoea (OSA)
- #Ocean Biomedical
- #ocular disease
- #ocular tearing
- #Ocuphire
- #odyssey
- #offering price
- #Office of Therapeutic Products (OTP)
- #older Americans
- #Oligofyer bioinformatics system
- #OligoPhore delivery platform
- #OliX Pharmaceuticals
- #Olvi-Vec
- #OLX72021
- #OMEGA
- #omicron
- #Omicron XBB.1.5 variant
- #once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)
- #Oncocyte- manufacturing process- transplant technology- distributable version- patented method- graft damage- transplant recipients- assay- donor derived cell-free DNA (dd-cfDNA)- early access launch- RUO kit- late Q4 2023- Josh Riggs (Onco
- #oncologists
- #Oncology
- #oncology indications
- #oncology practices
- #oncology programs
- #oncolytic virotherapy
- #oncolytic viruses
- #Oncolytics Biotech
- #OneOncology
- #Opdivo
- #operational challenges
- #ophthalmic conditions including nAMD.
- #opioid crisis
- #opioid settlement
- #optical devices.
- #Option
- #oral
- #oral antiviral
- #oral arsenic trioxide (OATO)
- #oral delivery
- #oral fertility drug program
- #oral nimodipine
- #oral oncology liquid manufacturing expertise
- #oral recombinant vaccines based on proprietary delivery platform
- #oral small molecule inhibitor
- #oral therapy
- #OraSure Technologies
- #Orbit study
- #Orchard Therapeutics
- #orelabrutinib
- #Oren Koren
- #ORLADEYO
- #orphan drug block
- #orphan drug designation.
- #Orphan Drug Designations
- #Orthogon
- #Orviglance
- #OSDI
- #Osemitamab (TST001)
- #Osimertinib
- #Osteogenesis Imperfecta (OI)
- #osteogenic
- #osteoporosis
- #OTC listing compliance
- #OTL-200
- #OTSUKA
- #out-of-pocket expenses
- #out-of-pocket expenses.
- #outcome measurements
- #outcomes
- #outsourcing
- #ovarian cancer
- #ovarian stimulation
- #OvarianCancer
- #over-the-counter eye drops
- #overall mortality.
- #overall response rate
- #overall response rate (ORR)
- #overall survival
- #overall survival (OS)
- #ovulation induction
- #Oxford Population Health
- #packaged foods
- #PAD4 inhibitor for autoimmune and oncology indications
- #Padcev
- #Paid time off
- #Pain
- #pain management treatment options
- #palatable oral solution
- #Palisade Bio
- #Palmitoylethanolamide (PEA)
- #Palvella
- #pamrevlumab
- #pancreatic cancer
- #pancreatic cancer model
- #pancreatic cancer stem cells (Bx PC3-CSCs)
- #pancreatic cancer therapies
- #pancreatic cysts
- #Pandemic
- #panic attacks
- #panic disorder
- #pap
- #papulopustular rosacea
- #Par Sterile Products
- #Paragraph IV Filing.
- #Paratus Sciences
- #Paridiprubart
- #parietal regions
- #Parkinson's disease
- #Parsippany
- #Part C results
- #Parthenon Therapeutics
- #partial clinical hold
- #partial response
- #Partner
- #partnership
- #partnership.
- #Partnerships
- #PASC
- #patent allowance
- #Patent Application
- #patent applications
- #Patent Cooperation Treaty (PCT)
- #patent lawsuits
- #patent protections
- #patent rights
- #pathogens
- #pathology of lethal pathogens.
- #pathophysiology of MDD.
- #Patient
- #patient access
- #patient access and technology solutions
- #patient access platform
- #patient enrollment
- #patient outcomes
- #patient-reported outcome questionnaire (SHAQ)
- #Patients
- #patients between two and five years of age
- #Pavan Cheruvu
- #PAX-101
- #PaxMedica
- #pay and benefits
- #PC
- #PCA001
- #PCI Study
- #PD-1
- #PD-1 inhibitor
- #PD-L1 inhibitor
- #PD-L1 inhibitor.
- #PD-L1 positive
- #PDS Biotechnology
- #PDS0101
- #PDUFA
- #PDUFA VII
- #peanut
- #Pediatric
- #Pediatric ADHD
- #pediatric and young adult patients
- #pediatric death
- #pediatric patients
- #pediatric RSV antibody
- #pediatric surgery
- #peer-reviewed journals
- #peer-reviewed research article
- #Pelareorep
- #Pembrolizumab
- #pembrolizumab (Keytruda®)
- #pemetrexed for injection
- #PEMRYDI RTU®
- #penalties
- #Peninsula
- #peptidylarginine deiminase 4 (PAD4) inhibitor
- #PER-001
- #perf
- #performance improvement with high-accuracy AI model for radiologists in one group but not the other group using low-accuracy AI model.
- #Perfusion Solution
- #Peripheral and Central Nervous System Drugs Advisory Committee
- #personalised medicine
- #Personality
- #personality disorder
- #personalized approach
- #personalized drug therapy.
- #personalized patient management decisions
- #PET Imaging
- #PET imaging centers
- #PET/CT imaging agent
- #PETNET Solutions Inc
- #pfizer
- #Pfizer/BioNTech
- #PFS data
- #PH10
- #Ph2a
- #PH80 nasal spray
- #Pharma
- #Pharma companies
- #pharmaceutical and biotechnology companies
- #pharmaceutical and biotechnology organizations
- #pharmaceutical companies
- #pharmaceutical companies Biogen and Pfizer
- #pharmaceutical manufacturers
- #pharmacies
- #pharmacodynamics
- #pharmacodynamics (PD)
- #pharmacokinetic and pharmacodynamic data
- #pharmacokinetic data
- #pharmacokinetics
- #pharmacokinetics (PK)
- #pharmacokinetics.
- #Pharmacology
- #pharmacy benefit managers.
- #Phase 1
- #Phase 1 clinical trial
- #Phase 1 clinical trial.
- #Phase 1 study
- #Phase 1 trial
- #Phase 1 Trials
- #Phase 1/2
- #Phase 1/2 clinical trial
- #Phase 1/2 study
- #Phase 1/2 trial
- #Phase 1a/b study
- #Phase 1b Trial
- #Phase 1b/2 study
- #Phase 1b/2 trial
- #phase 2
- #Phase 2 clinical study
- #Phase 2 clinical trial
- #Phase 2 GI.1 challenge study
- #Phase 2 Liver Cancer Trial
- #Phase 2 REVIVE study
- #Phase 2 SEQUEL Study
- #Phase 2 SPAN clinical trial
- #Phase 2 study
- #Phase 2 study.
- #Phase 2 topline data readout
- #Phase 2 trial
- #Phase 2/3 study
- #Phase 2a clinical trial.
- #phase 2b
- #Phase 2B development
- #Phase 2b SPAN trial
- #Phase 2b study
- #Phase 3
- #Phase 3 Clinical Program
- #Phase 3 clinical trial
- #Phase 3 Clinical Trials
- #Phase 3 confirmatory randomized controlled trial
- #Phase 3 Program
- #Phase 3 safety trial protocol
- #Phase 3 segment
- #Phase 3 SPOTLIGHT and GLOW clinical trials.
- #Phase 3 study
- #Phase 3 trial
- #Phase I
- #Phase I clinical trials.
- #Phase I-IV clinical trial management
- #Phase I/II clinical trials
- #Phase I/II data
- #Phase I/II study
- #Phase I/IIa clinical trial
- #Phase Ib study
- #Phase II studies
- #Phase II study
- #Phase II trial
- #Phase IIa
- #Phase IIa study
- #Phase IIb
- #Phase IIb PARADIGM clinical trial
- #Phase IIb trial
- #Phase III
- #Phase III ASSERT study
- #Phase III clinical study
- #phase III clinical trial
- #Phase III study
- #Phase III trial
- #Phase III trial in lung cancer
- #Phase III trial.
- #Phil Inc.
- #PhilRx Platform
- #phoenix
- #Phylos
- #physical factors
- #physical measurements
- #Physio-Assist
- #pill burden reduction.
- #Pillar Biosciences
- #pilot randomized controlled trials
- #PIM1 kinase inhibitor
- #PIP-101
- #pipeline
- #pipeline development
- #pipeline research and development
- #pipeline treatments
- #pitolisant
- #pivotal clinical trial.
- #pivotal Phase 2/3 clinical trial
- #pivotal Phase III ALS study
- #pivotal trial
- #PK
- #pKa
- #PLACEBO
- #placebo-controlled
- #placebo-controlled trial
- #placement agent's fees and other offering expenses
- #plans
- #plasma neurofilament
- #plasma skin therapy
- #plasmid and viral vector process development
- #platform growth.
- #platinum resistant ovarian cancer
- #Plus Therapeutics
- #PMN
- #Point-of-Care Blood Volume Analyzer
- #PolarityTE
- #polyclonal antibody therapeutic.
- #polycystic ovary syndrome (PCOS)
- #polycythemia vera
- #polycythemia vera (PV)
- #PolyPid
- #Pomalidomide
- #POP1 project
- #Portfolio
- #PORTICO trial
- #positive findings
- #positive preliminary topline data
- #positive results
- #positive topline results
- #POSLUMA
- #Post-COVID Conditions
- #post-operative ileus.
- #post-traumatic stress disorder (PTSD)
- #postdoctoral cancer research
- #postoperative bowel function
- #potential approval
- #PRA-023
- #PRA023
- #Prader-Willi syndrome
- #pre-BLA meeting
- #pre-cirrhotic liver fibrosis due to NASH.
- #pre-clinical study
- #pre-filled syringe
- #pre-formed fibrils (PFFs)
- #pre-funded warrants
- #Pre-Term Deliveries
- #Precedex®
- #precision genetic test
- #precision medicine
- #Precision Medicines
- #precision oncology
- #Precision Promise
- #PrecisionCHD™
- #preclinical data
- #preclinical pharmacologic data
- #preclinical pharmacology and safety toxicology studies.
- #preclinical studies
- #preclinical testing standards
- #preeclampsia
- #preferred investment options
- #prefrontal cortex
- #PreHevbri
- #preliminary activity
- #preliminary data
- #premature atrial contractions
- #premature ventricular contractions
- #Premier Medical
- #Prescription Drug User Fee Act (PDUFA)
- #prescription drugs
- #prescription drugs.
- #prescription process improvement.
- #Presidential Poster Competition
- #prevalence of Squamous Cell Carcinoma (SCC) lesions
- #PREVDUO
- #PREVENT trial
- #prevention
- #prevention of post-surgical abdominal adhesions
- #preventive treatment
- #price hikes
- #pricing.
- #Prima Biomed Limited
- #primary and secondary endpoints
- #primary endpoint
- #primary endpoints
- #Primary Immune Thrombocytopenia
- #primary sclerosing cholangitis (PSC)
- #primary vitreoretinal lymphoma
- #PrimeC
- #principal investigators
- #prior authorization process (PA)
- #Priority Review
- #priority review voucher (PRV)
- #Prism
- #private placement
- #private property
- #Priveterra
- #PRMT5 inhibitor
- #pro-forma cash balance
- #proactive elective revascularization by stenting or CABG poses economic cost to the system but no mortality or morbidity benefits for patients with stable angina but instead leads to excess mortality. current medications used for treating angina in the U
- #probes
- #product approval
- #Product Development
- #productivity
- #Profervia®
- #Professional Services group
- #progestogen
- #Prognos Health
- #prognostically unfavorable patient population
- #program
- #PROGRESS
- #PROGRESS study
- #progression free survival (PFS)
- #progression free survival endpoint.
- #progression-free survival
- #progression-free survival (PFS)
- #progressive familial intrahepatic cholestasis
- #Proliferation-Associated Genes
- #Prometheus Biosciences
- #ProMIS
- #promising and innovative cancer research
- #Promontory Therapeutics
- #Promosome
- #proof-of-concept study
- #proof-of-concept study.
- #Propanc Biopharma
- #property rights
- #propionic acidemia (PCCB)
- #proprietary drug
- #proprietary HER2 and HER3 antibody drug conjugates
- #proprietary manufacturing platform
- #ProSense® System
- #prospective crossover study design
- #prospectus supplement
- #prostate cancer
- #Prostate Cancer.
- #Protagonist Therapeutics
- #protein arginine methyltransferase 5 (PRMT5) inhibitor
- #protein engineering technology
- #proteinuria
- #proteinuria.
- #protocol.
- #Prototyping
- #provider network management solutions
- #PRP
- #PRTH-101
- #PSMA+
- #psoriasis
- #psoriatic arthritis
- #psychedelic medicine therapies
- #psychedelic treatment
- #Psychotherapy
- #PT-112
- #PTCL cohort
- #PTH
- #PTSD
- #public key
- #public offering
- #public use
- #publication
- #Pulmonary hypertension associated with Interstitial Lung Disease (ILD)
- #Pulmonx Corporation
- #pyrrolopyrimidine-based
- #Q BioMed Inc.
- #Qalsody
- #Qalsody (tofersen)
- #QTORIN
- #quantitative electroencephalogram (qEEG)
- #Quantum Leap Healthcare
- #Quell Therapeutics
- #Quest
- #quiet quitting
- #Quince
- #R&D
- #R&D capability
- #R-CHOP-like regimen
- #R/R AML
- #RA Capital Management
- #rabbit-derived anti-thymocyte globulin (rATG)
- #racketeering
- #RaDaR registry
- #radiofrequency ablation
- #radiofrequency products
- #radiolabeling.
- #radiologists
- #Radiologists' Diagnostic Determination
- #radiology residents
- #radiotherapy
- #Ram Sasisekharan
- #randomized
- #randomized controlled trial
- #randomized phase II study
- #randomized withdrawal trial
- #Ranexa
- #Rani Therapeutics
- #RaniPill®
- #ransomware attacks
- #rapamycin
- #rare
- #rare cancer conditions
- #rare disease
- #rare disease biopharmaceutical company.
- #rare diseases
- #rare genetic diseases
- #Rare Pediatric Disease designation
- #Rarecells
- #Ratio of Treated to Total Tumor Volume.
- #rats.
- #Raynaud's Phenomenon
- #RaySearch
- #RCT
- #RDCC
- #RDN
- #reactive aldehyde species (RASP)
- #ready-to-use presentation
- #real-world evidence registry
- #rec-PRP label
- #Recce Pharmaceuticals Ltd
- #RECCE® 327
- #receptor tyrosine kinase KIT
- #recipients
- #RECIST 1.1
- #Recludix
- #recombinant adeno-associated virus (rAAV)
- #recombinant adeno-associated virus (rAAV) vectors
- #recommended Phase 2 dose (R2PD)
- #recommended phase 2 dose (RP2D)
- #RECONNOITER study
- #ReCor
- #Recruitment
- #Recurrence
- #recurrence and duration of illness
- #recurrent and metastatic breast cancer
- #recurrent glioblastoma (rGBM)
- #red blood cell transfusion dependence
- #RedHill Biopharma
- #reduce symptoms in 28 days
- #REDUCE-IT trial.
- #reduction in cognitive decline
- #refractory setting
- #regenerative medicine
- #Regeneron Pharmaceuticals
- #registered direct offering
- #registered prescription drugs
- #registrational study
- #regulatory applications
- #regulatory CD8 T cells
- #regulatory decisions
- #regulatory environment
- #regulatory pathway
- #regulatory roadblocks
- #regulatory verdict
- #regulatory verdict.
- #reinnervation
- #Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
- #relapsed/refractory AML.
- #Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
- #relative theta power
- #ReleaDom™
- #ReletexTM
- #Reliefband Technologies
- #remission
- #remission of symptoms
- #remote monitoring.
- #remote operation capabilities
- #remyelination
- #renal drug portfolio
- #renal excretion
- #renal NLRP3 inflammasome activation
- #renewable energies
- #RenovoRx
- #replacement search
- #Reproxalap
- #research
- #research discoveries
- #research funding
- #research grant awards
- #research institutes
- #researchers
- #Resignation
- #resmetirom
- #Resources
- #ReSPECT™ Clinical Trials
- #Respiratory
- #Respiratory Care
- #respiratory care.
- #Respiratory Health business
- #respiratory pathogens
- #respiratory syncytial virus
- #respiratory syncytial virus (RSV)
- #restructuring
- #Retention
- #retinal and refractive eye disorders
- #retinitis pigmentosa 45
- #retrospectively collected chest radiographs
- #Rett Syndrome
- #return of gastrointestinal function
- #return to sleep and wakefulness
- #revaccination.
- #RevCore thrombectomy catheter
- #Reveal Lasers
- #REVEAL Phase 1/2 trial.
- #Revenue
- #REVERT LIVER CANCER Trial
- #review
- #Revised Amyotrophic Lateral Sclerosis Functional Rating Scale.
- #Revival Healthcare Capital
- #RevolKa Ltd.
- #RF Trident technology
- #RFID
- #rhenium (186Re) obisbemeda
- #rheumatoid arthritis
- #Richard Mulligan.
- #Richmond Albuquerque Kansas City Knoxville.
- #right of first refusal
- #Rights Offering
- #rimegepant
- #RingerTM
- #RINGSIDE
- #rising drug prices
- #rising PSA
- #risk profile
- #risk stratification
- #risk-to-benefit profile
- #RiskScore
- #Rituximab
- #RNA
- #RNA cell therapy
- #RNA therapeutics.
- #RNAi therapeutics
- #RNAi-based technology
- #robotic pill
- #robust pipelines
- #Roche
- #Ronald Martell
- #ropeginterferon alfa-2b
- #Rosalind Franklin University
- #royalties
- #RUBY trial
- #rule of law
- #rusfertide
- #SaaS
- #SAB Biotherapeutics
- #SAB-142
- #Safety
- #safety and efficacy data
- #safety and efficacy profile.
- #safety and tolerability
- #safety and tolerability data.
- #safety and tolerability profile
- #safety concerns
- #safety data
- #safety evidence
- #safety levels
- #safety profile
- #safety signal
- #safety signals
- #safety signals (ARIA)
- #sahara
- #Sale
- #sales
- #SANOFI
- #SARA-31
- #sarcoidosis
- #sarcopenia
- #Sarepta
- #SARS-CoV-2
- #SARS-CoV-2 Vaccination
- #SARS-CoV-2 variants
- #SARS-CoV2 inhibition
- #Saudi Arabia
- #Saudi Food and Drug Authority
- #SBIR
- #SBS-IF
- #SC0062
- #Scale
- #Scientific Health Development
- #SciSparc
- #SciSparc- Phase IIb clinical trial- SCI-110- Tourette Syndrome- Germany- Federal Institute for Drugs and Medical Devices (BfArM)- Hannover Medical School- Yale Child Study Center- Yale School of Medicine- Tel Aviv Sourasky Medical Center (Sour
- #Scleroderma
- #Scope 3 emissions
- #SCORPIO-PEP study.
- #screening assays
- #SDT-001 (localized version of AKL-T01 / EndeavorRx)
- #SDVOSB procurement goals.
- #seagen
- #Seagen's Padcev
- #Searx
- #Secarna Pharmaceuticals
- #Section 4(a)(2)
- #secured debt obligations
- #Securities Act of 1933
- #Securities and Exchange Commission (SEC)
- #securities purchase agreement
- #sedation
- #seed round
- #Seelos Therapeutics
- #seizure clusters
- #seizure clusters/acute repetitive seizures
- #selected TILs
- #Selective Estrogen Receptor Modulator (SERM)
- #self-administered pre-filled pen (autoinjector)
- #self-administered prefilled syringe
- #self-sampling
- #senescence
- #Senhance
- #Seoul National University Hospital
- #separation of powers
- #Series A financing round.
- #Series A funding round
- #Series B financing
- #Series B funding round
- #Series D
- #serine protease inhibitor
- #seroprotection rate
- #serotypes
- #SerpinPC
- #serum IgA
- #serum IgG
- #serum immune responses
- #serum neutralizing titers
- #serum samples
- #Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor
- #services
- #Setrusumab
- #settlement agreement
- #severe LRTD
- #SFDA
- #shake-up
- #share repurchase program
- #shareholder approval
- #shareholder value
- #shareholder value.
- #shareholders
- #Shares
- #shelf registration statement
- #SHIELD II
- #Shionogi
- #Shorla Oncology
- #SHP2
- #sickle cell disease
- #Siemens Healthineers Company
- #Sight
- #sigmoidoscopes
- #signs and symptoms of malabsorption
- #Simcha Therapeutics
- #Simufilam
- #Simvastatin
- #single islet transplantation outcomes.
- #siRNA therapeutic
- #Sirnaomics
- #Sirona Biochem
- #SK bioscience
- #SK bioscience- Peter Doherty Institute for Infection and Immunity- collaboration agreement- influenza research- biomedical research institute- vaccines- antivirals- influenza biology- low- and middle-income countries- new influenza vaccine pla
- #SKG0106
- #skin toxicities
- #skincare
- #SkinTE
- #Skyline Therapeutics
- #Sleep disorders
- #sleep disturbances
- #SLP
- #SLS-002
- #small business innovative research (SBIR)
- #small cell lung cancer (SCLC)
- #small intestine
- #small molecule inhibitors
- #SmartECG technology
- #SNMMI Annual Meeting
- #Soaak
- #social factors
- #social responsibility
- #SOD1 ALS
- #SOD1-ALS
- #sodium phenylbutyrate
- #soft tissue sarcomas
- #solid tumors
- #solid tumors.
- #somatostatin receptor positive neuroendocrine tumors (NETs)
- #Sona Nanotech
- #Sonelokimab (SLK)
- #Sorrento
- #Souffle Therapeutics
- #SP0202
- #SPA
- #spain
- #sparta
- #spastic paraplegia 50
- #Spaya™ retrosynthesis AI technology.
- #Spikevax vaccine.
- #spin-off
- #spinal cord injuries
- #spinal implant market.
- #Spine surgery
- #spleen volume reduction
- #spliceosome mutation
- #spliceosome mutations
- #spliceosome mutations in MDS and lung tumors
- #spliceosome proteins mutations
- #Squamous Cell Carcinoma in situ
- #SSH
- #ST-067
- #stable disease
- #Stage 2
- #Stage I Cutaneous Melanoma (CM)
- #standard of care
- #standard of care chemotherapy
- #standard of care therapy
- #Standardization
- #STARBURST study
- #STAT3 Degrader KT-333
- #STAT3 Inhibitor
- #STAT6
- #statin
- #statin therapy
- #STEAP1 and 5T4.
- #Stelara
- #Stelios Papadopoulos
- #Stem Cell Therapy
- #stem cell transplant conditioning regimes
- #Stock Option Plan
- #stockholder value maximization failure
- #stockholders of record
- #stool weight
- #STP705
- #Strategic
- #strategic alternatives
- #strategic collaboration
- #strategic financing
- #strategic partnership
- #strategic planning
- #strategic platform license
- #stress response
- #STRIVE-ON
- #Study
- #Study 301 (CLARITY AD)
- #study launch
- #sub-group of subjects
- #subcutaneous efgartigimod
- #subcutaneous injections
- #subgroups
- #subject
- #substrate competitive inhibitor
- #subvariants
- #success rate
- #suicide attempt.
- #Sumitomo Pharma Co.
- #Sumitomo Pharma Oncology
- #Sun Pharmaceuticals
- #SunMed Group Holdings
- #Suono Bio
- #super office
- #superoxide dismutase 1-ALS
- #supply issues
- #suramin
- #Surface Oncology
- #surge
- #Surgery
- #survival outcomes
- #Susan G. Komen
- #Susan Langer
- #sustainability report
- #Sustainable Impact Award
- #SVB Securities
- #Swiss Phase I Trial
- #SWOG S1826 trial results.
- #symptom score improvement. Tags: Sumitomo Pharma Oncology
- #symptomatic obstructive hypertrophic cardiomyopathy (HCM)
- #symptomatic SARS-CoV-2 infection
- #Symptoms
- #synaptic function
- #SynaptixBio
- #Synaptogenix
- #Syndax
- #synthetic lethality between PRMT5 inhibition and spliceosome protein mutations
- #synthetic recombinant proenzymes
- #systemic lupus erythematosus.
- #systemic radiation exposure
- #Systemic Sclerosis (SSc)
- #T cell
- #T cell response
- #T cell-mediated killing
- #T-cell lymphoma
- #T-cell therapy
- #T-cells
- #T-regulatory (Treg) cells
- #T-regulatory cells
- #Tagrisso
- #Tailoring Therapy
- #TakeAim Leukemia study
- #Takeda
- #talent market
- #talent war
- #Talicia
- #tamoxifen
- #TAMP
- #Tampa
- #TANGO
- #target knockdown
- #targeted biologic therapeutics.
- #Targeted Hyperthermia Therapy
- #targeted patients
- #targeted therapies
- #Targeting
- #Tau protein antigens
- #Tau protein antigens.
- #tau proteins
- #taurursodiol
- #tax-free distribution
- #Taysha Gene Therapies
- #TBUT
- #TCv8
- #TD Cowen.
- #Team
- #Tecentriq
- #Technologies
- #technology
- #technology platform
- #Teleflex
- #Telix Pharmaceuticals Limited
- #TellBio
- #TellDx Platform
- #temporal regions
- #tenapanor
- #Tennessee
- #Tepezza
- #teriparatide.
- #test
- #testing
- #TEVA
- #Teva Pharmaceuticals
- #TFC-039
- #TFC-1067
- #TFC-1326
- #TFChem
- #TGF-β1 gene expression
- #The Journal of Immunology
- #The Lancet
- #Ther
- #theranostic scouting study.
- #therapeutic antibody.
- #therapeutic benefit
- #therapeutic effect of blocking CCL24
- #Therapeutic Index and Brain Exposure Optimization (TIBEO)
- #therapeutic outcomes.
- #therapeutic targets
- #therapeutic vaccine
- #therapeutics
- #thermo
- #Thermo Fisher Scientific- Metrios 6 Scanning Transmission Electron Microscope ((S)TEM)- automation- metrology solution- productivity- data quality assurance- semiconductor manufacturing- hardware- machine learning techniques- optimization perf
- #Third Pole Therapeutics
- #thrombocytopenia
- #thrombosis and embolism
- #THRβ full agonist
- #thyroid hormone receptor (TSHR)
- #TIBEO discovery engine
- #tibial fractures
- #TILs
- #tipifarnib
- #tislelizumab
- #TKI
- #tld
- #TLR4 antagonist
- #TLX250-CDx
- #TNF-like ligand 1A (TL1A)
- #TNG462
- #TNGX
- #toddlers aged 12 to 15 months
- #Togaviridae virus
- #tolerability
- #tolerability data
- #Toll-like Receptor 4 (TLR4)
- #Tonix Pharmaceuticals
- #Tonmya™ (TNX-102 SL
- #top performers
- #topline data
- #topline results
- #toripalimab
- #Total Dose in Distribution Volume
- #total ocular score
- #toxicity reduction
- #TP-3654
- #TPG Ventures
- #trading symbol "FTRE"
- #traditional approval
- #Transcenta
- #TransCode Therapeutics
- #transfusion independence
- #transfusion-dependent beta thalassemia
- #transgene genome encoding anti-VEGF protein
- #Translational
- #translational activities
- #Transmission
- #trastuzumab
- #treatment
- #treatment development.
- #treatment effect
- #Treatment of Narcolepsy
- #Treatment options
- #Treg therapies
- #tri-specific antibodies
- #Trial
- #trials in humans
- #Triever16 Curve catheter
- #triglyceride levels
- #triple immunotherapy combination
- #TROPION-Lung01 Phase III trial
- #TROSIG™
- #truncated protein
- #trypsinogen
- #TSHA-102
- #TSHA-120
- #TSX
- #TTI-101
- #TTX-MC138